Evaluation of AI-Mouse Use in Patients With Hand and Wrist Conditions

July 10, 2026 updated by: Nazarbayev University
People with hand and wrist conditions, such as carpal tunnel syndrome or hand injuries, often experience pain and discomfort when using a computer mouse. This study will evaluate a new artificial intelligence (AI)-assisted computer input system ("AI-mouse") designed to reduce the amount of hand movement needed during computer tasks. Participants will complete short computer-based tasks using both a conventional mouse and the AI-assisted system while researchers measure task performance, muscle activity using surface electromyography (EMG), and participants' ratings of pain, physical strain, and usability. The study aims to determine whether the AI-assisted system can reduce physical effort and muscle load while maintaining effective computer interaction. Findings may help improve accessible computer technologies and support the development of ergonomic tools for people with hand and wrist impairments.

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Not yet recruiting

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Interventional

Enrollment (Estimated)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
15

Phase

Phase

The stage of a clinical trial studying a drug or biological product, based on definitions developed by the U.S. Food and Drug Administration (FDA). The phase is based on the study's objective, the number of participants, and other characteristics. There are five phases: Early Phase 1 (formerly listed as Phase 0), Phase 1, Phase 2, Phase 3, and Phase 4. Not Applicable is used to describe trials without FDA-defined phases, including trials of devices or behavioral interventions.
  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact

The name and contact information for the person who can answer enrollment questions for a clinical study. Each location where the study is being conducted may also have a specific contact, who may be better able to answer those questions.

Study Contact Backup

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Adults aged 18-65 years
  • Diagnosis of a hand or wrist condition, including carpal tunnel syndrome or hand/wrist injury.
  • Receiving care at the Hand Surgery Department of the National Scientific Center of Traumatology and Orthopedics.
  • Medically stable and assessed by a study physician as able to safely perform light computer-based hand movements.
  • Able to understand the study procedures and provide written informed consent.
  • Normal or corrected-to-normal vision sufficient to complete computer-based tasks.

Exclusion Criteria:

  • Severe pain or acute symptoms that may be aggravated by computer task performance.
  • Postoperative restrictions limiting hand or wrist movement.
  • Severe motor impairment preventing completion of the study tasks.
  • Cognitive or neurological disorders that interfere with understanding study procedures or task performance.
  • Uncorrected visual impairment that interferes with computer use.
  • Any medical condition that, in the opinion of the study physician, would make participation unsafe.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Supportive Care
  • Allocation: Non-Randomized
  • Interventional Model: Crossover Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm

Participant Group / Arm

A group or subgroup of participants in a clinical trial that receives a specific intervention/treatment, or no intervention, according to the trial's protocol.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
Active Comparator: Conventional Mouse
Participants perform standardized computer pointing tasks using a conventional computer mouse. Performance (task completion time, error rate, throughput), surface electromyography (EMG) of upper-limb muscles, and participant-reported outcomes (pain, physical strain, and usability) are assessed during task completion.
Device: Conventional Computer Mouse
A standard computer mouse used for conventional point-and-click interaction. Participants complete the same standardized computer tasks as in the experimental condition, allowing direct comparison of task performance, upper-limb muscle activity measured by surface electromyography (EMG), and participant-reported pain, physical strain, and usability.
Experimental: AI-Mouse (Preview-Accept-Discard [PAD] System)
Participants perform the same standardized computer tasks using the AI-Mouse, a predictive human-computer interaction system based on the Preview-Accept-Discard (PAD) paradigm. The system generates AI-assisted action suggestions that can be accepted or discarded using minimal keyboard input, reducing cursor movement. Performance, surface electromyography (EMG), and participant-reported outcomes (pain, physical strain, and usability) are assessed during task completion.
Device: AI-Assisted Computer Input System
A non-invasive computer input system that uses artificial intelligence to predict the user's intended on-screen action. Instead of relying primarily on continuous cursor movement and mouse clicking, the system presents predicted actions that participants can preview, accept, or discard using minimal keyboard input. The intervention is designed to reduce repetitive hand movements during computer interaction while preserving user control. Participants complete standardized computer tasks using the system during a single study session lasting less than four minutes.

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
APDF90 surface electromyography (sEMG) amplitude
Time Frame: Baseline (during each intervention condition on Day 1)
90th percentile amplitude probability distribution function (APDF90) of the processed sEMG envelope recorded from selected upper-limb muscles during standardized computer tasks.
Baseline (during each intervention condition on Day 1)
Muscular rest time
Time Frame: Baseline (during each intervention condition on Day 1)
Percentage of task duration during which the processed sEMG envelope remained below the predefined muscular-rest threshold of 2 µV.
Baseline (during each intervention condition on Day 1)

Secondary Outcome Measures

Secondary Outcome Measures

In a clinical study's protocol, a planned outcome measure that is not as important as the primary outcome measure for evaluating the effect of an intervention but is still of interest. Most clinical studies have more than one secondary outcome measure.
Outcome Measure
Measure Description
Time Frame
Integrated squared dynamic acceleration
Time Frame: Baseline (during each intervention condition on Day 1)
Cumulative dynamic movement workload measured by tri-axial accelerometry and expressed as integrated squared dynamic acceleration (mG²·s).
Baseline (during each intervention condition on Day 1)
90th percentile dynamic acceleration
Time Frame: Baseline (during each intervention condition on Day 1)
Peak dynamic movement intensity measured by tri-axial accelerometry and expressed as the 90th percentile of dynamic acceleration (mG).
Baseline (during each intervention condition on Day 1)
Task completion time
Time Frame: Baseline (during each intervention condition on Day 1)
Time required to complete the standardized computer task using the conventional mouse and the AI-assisted computer input system.
Baseline (during each intervention condition on Day 1)
Error rate
Time Frame: Baseline (during each intervention condition on Day 1)
Percentage of incorrect target selections during the standardized computer task
Baseline (during each intervention condition on Day 1)
Self-reported pain
Time Frame: Immediately after each intervention condition on Day 1
Participant-reported hand and wrist pain after completing each intervention condition, assessed using a numeric rating scale
Immediately after each intervention condition on Day 1

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
Nazarbayev University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
July 1, 2026

Primary Completion (Estimated)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
September 1, 2026

Study Completion (Estimated)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
October 1, 2026

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
June 30, 2026

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
July 10, 2026

First Posted (Actual)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
July 16, 2026

Study Record Updates

Last Update Posted (Actual)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
July 16, 2026

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
July 10, 2026

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
July 1, 2026

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • 1220/02042026

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings